Thalidomide in front line treatment in multiple myeloma: Serious risk of venous thromboembolism and evidence for thromboprophylaxis [10]

Journal of Thrombosis and Haemostasis

Volumn 2, Issue 11, 2004, Pages 2063-2065

  Rus, C ^a   Bazzan, M ^a   Palumbo, A ^b,c   Bringhen, S ^b,c   Boccadoro, M ^b,c  

^a Ospedale Evangelico Valdese   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c GISMM   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ENOXAPARIN; MELPHALAN; PREDNISONE; THALIDOMIDE;

ANTIANGIOGENIC ACTIVITY; ARTERY THROMBOSIS; CANCER STAGING; DRUG EFFICACY; DRUG SURVEILLANCE PROGRAM; HUMAN; INCIDENCE; LETTER; LUNG EMBOLISM; MULTIPLE MYELOMA; NEUROPATHY; PREVALENCE; PRIORITY JOURNAL; RECURRENCE RISK; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; SURVIVAL; TERATOGENICITY; TUMOR REGRESSION; VENOUS THROMBOEMBOLISM;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FIBRINOLYTIC AGENTS; HUMANS; MULTIPLE MYELOMA; RISK FACTORS; THALIDOMIDE; THROMBOEMBOLISM; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 13244271291     PISSN: 15387933     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2004.00931.x     Document Type: Letter

References (16)

1. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-71; Erratum N Engl J Med 2002; 342:364
2. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, Badros A, Zangari M, Anaissie E, Epstein J, Shaughnessy J, Ayers D, Spoon D, Tricot G. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide. identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492-4.
3. Palumbo A, Giaccone L, Bertola A, Pregno P, Bringhen S, Rus C, Triolo S, Gallo E, Pileri A, Boccadoro M. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 2001; 86: 399-403.
4. Leleu X, Magro L, Fawaz A, Bauters F, Facon T, Yakoub-Agha I. Efficacy of a low dose of thalidomide in advanced multiple myeloma. Blood 2002; 100: 1519-20.
5. Schey SA, Cavenagh J, Johnson R, Child JA, Oakervee H, Jones RW. An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment. Leuk Res 2003; 27 909-14.
6. Tosi P, Zamagni E, Cellini C, Ronconi S, Patriarca F, Ballerini F, Musto P, Di Raimondo F, Ledda A, Lauria F, Masini L, Gobbi M, Vacca A, Ria R, Cangini D, Tura S, Baccarani M, Cavo M. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica 2002; 87: 408-14.
7. Palumbo A, Bertola A, Falco P, Rosato R, Cavallo F, Giaccone L, Bringhen S, Musto P, Pregno P, Caravita T, Ciccone G, Boccadoro M. Efficacy of low dose thalidomide and dexamethasone as first savage regimen in multiple myeloma. Hematol J 2004; 5: 318-24.
8. Yakoub-Agha I, Attal M, Dumontet C, Delannoy V, Moreau P, Berthou C, Lamy T, Grosbois B, Dauriac C, Dorvaux V, Bay JO, Monconduit M, Harousseau JL, Duguet C, Duhamel A, Facon T. Thalidomide in patients with advanced multiple myeloma. a study of 83 patients - report of the Intergroupe Francophone du Myelome (IFM). Hematol J 2002; 3: 185-92.
9. Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexanian R. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 2003 June; 121: 768-71.
10. Dimopoulos MA, Zervas K, Kouvatseas G, Galani E, Grigoraki V, Kiamouris C, Vervessou E, Samantas E, Papadimitriou C, Economou O, Gika D, Panayiotidis P, Christakis I, Anagnostopoulos N. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 2001; 12: 991-5.
11. Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R, Geyer SM, Iturria N, Kumar S, Lust JA, Kyle RA, Greipp, PR, Witzig TE. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003; 17: 775-9.
12. Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR, Geyer S, Iturria N, Fonseca R, Lust JA, Kyle RA, Witzig TE. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 4319-23.
13. Zangari M, Barlogie B, Thertulien R, Jacobson J, Eddleman P, Fink L, Fassas A, Van Rhee F, Talamo G, Lee CK, Tricot G. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clin Lymphoma 2003; 4: 32-5.
14. Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, Gopal AV, Morris C, Toor A, Siegel E, Fink L, Tricot G. Increased risk of deepvein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98: 1614-5.
15. Barbui T, Falanga A. Thalidomide and thrombosis in multiple myeloma. J Thromb Haemost 2003; 1: 421-2.
16. Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A, Morris C, Fink L, Tricot G. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002; 100: 1168-71.